Dupixent Receives FDA Approval as First New Targeted Therapy for Chronic Spontaneous Urticaria in Over a Decade
"Finally, some hope for those suffering from CSU!"
"What does this mean for patients already on other treatments?"
"Is Dupixent suitable for all CSU patients?"
"Amazing news! Can't believe it's been over a decade."
"Will insurance cover this new treatment?"
"How soon can patients start using Dupixent after approval?"
"I hope this helps my friend who suffers from CSU!"
"Interesting! I wonder about the long-term effects."
"This could change lives; I'm excited!"
"Can it be administered at home, or only in clinics?"
2025-04-18T15:15:00.000Z
Marco Rinaldi
Source of the news: www.globenewswire.com